Allergy Therapeutics plc (LON:AGY) shares crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $11.59 and traded as low as $12.28. Allergy Therapeutics shares last traded at $12.28, with a volume of 59,000 shares traded.
Separately, FinnCap restated a “corporate” rating on shares of Allergy Therapeutics in a report on Thursday, July 11th.
The business’s 50 day moving average is GBX 11.60 and its 200-day moving average is GBX 11.90. The company has a debt-to-equity ratio of 6.20, a quick ratio of 3.08 and a current ratio of 3.74. The firm has a market capitalization of $78.57 million and a price-to-earnings ratio of -24.70.
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.